A Case of Lymphocytic Myocarditis with Eosinophilic Degranulation Successfully Treated with Steroid Therapy.
Journal
Case reports in cardiology
ISSN: 2090-6404
Titre abrégé: Case Rep Cardiol
Pays: United States
ID NLM: 101576452
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
04
2020
revised:
23
07
2020
accepted:
24
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
A 49-year-old woman was admitted with suspicion of acute myocarditis. On the next day after admission, her serum troponin I level continued to rise, indicating progression of myocardial damage. Moreover, her symptoms persisted, and left ventricular ejection fraction did not improve. Because of a predominant infiltration of lymphocytes in the myocardial specimens, lymphocytic myocarditis was diagnosed. However, a close observation of the specimens revealed eosinophil degranulation. Based on this finding, intravenous steroid therapy was initiated. High-dose methylprednisolone led to rapid and appreciable improvements in symptoms and left ventricular function within 12 hours after the first administration, which was followed by normalization of serum troponin I level. Steroid therapy was switched to oral administration and tapered carefully. There was no recurrence of left ventricular dysfunction or elevation of serum troponin I level. In eosinophilic myocarditis, eosinophil degranulation has been recognized as an important finding associated with progression of inflammation and myocardial damage. However, no attention has been paid to the presence and clinical implications of eosinophil degranulation in lymphocytic myocarditis. This case indicates that eosinophil degranulation in lymphocytic myocarditis may be an important finding associated with a high therapeutic response to steroid therapy.
Identifiants
pubmed: 32774931
doi: 10.1155/2020/8887726
pmc: PMC7407015
doi:
Types de publication
Case Reports
Langues
eng
Pagination
8887726Informations de copyright
Copyright © 2020 Tomoko Inoue et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this article.
Références
Am J Med. 2018 Nov;131(11):e465-e466
pubmed: 30025879
Can J Cardiol. 2006 Dec;22(14):1233-7
pubmed: 17151774
J Am Coll Cardiol. 2012 Feb 28;59(9):779-92
pubmed: 22361396
N Engl J Med. 2011 Jul 14;365(2):187-8
pubmed: 21751935
J Immunol. 1996 Aug 1;157(3):1219-25
pubmed: 8757629
Biochem J. 1982 Apr 15;204(1):75-80
pubmed: 7115333
Heart Fail Rev. 2018 Jul;23(4):573-581
pubmed: 29862463
Herz. 2018 Aug;43(5):423-430
pubmed: 29947834
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
Lancet. 2003 Oct 25;362(9393):1378-80
pubmed: 14585641
Eur J Cardiothorac Surg. 2013 Feb;43(2):379-82
pubmed: 22564805
Clin Res Cardiol. 2016 Sep;105(9):794-6
pubmed: 27091051
N Engl J Med. 1990 Nov 29;323(22):1542-5
pubmed: 2233934